• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Glaucoma - Pipeline Review, H2 2011 - Product Image

Glaucoma - Pipeline Review, H2 2011

  • Published: September 2011
  • 174 pages
  • Global Markets Direct

Glaucoma - Pipeline Review, H2 2011

Summary

Global Markets Direct’s, 'Glaucoma - Pipeline Review, H2 2011', provides an overview of the Glaucoma therapeutic pipeline. This report provides information on the therapeutic development for Glaucoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Glaucoma. 'Glaucoma - Pipeline Review, H2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Glaucoma.
- A review of the Glaucoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- READ MORE >



List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Glaucoma Overview
Therapeutics Development
An Overview of Pipeline Products for Glaucoma
Glaucoma Therapeutics under Development by Companies
Glaucoma Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Glaucoma Therapeutics - Products under Development by Companies
Glaucoma Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Glaucoma Therapeutics Development
Alcon, Inc.
Bausch & Lomb Incorporated
Allergan, Inc.
QLT Inc.
AstraZeneca PLC
Santen Incorporated
Quark Pharmaceuticals, Inc.
Merck & Co., Inc.
Santen Pharmaceutical Co., Ltd.
Novagali Pharma SA
Alseres Pharmaceuticals, Inc.
Kowa Company, Ltd.
Pfizer Inc.
Sun Pharmaceutical Industries Limited
ISTA Pharmaceuticals, Inc.
OphthalmoPharma Ltd.
InSite Vision Incorporated
Proneuron Biotechnologies, Inc.
Can-Fite BioPharma Ltd.
Lpath, Inc.
ACADIA Pharmaceuticals Inc.
Lexicon Pharmaceuticals, Inc.
Phytopharm Plc
Asterand plc.
Resverlogix Corp.
Sirion Therapeutics, Inc.
Summit Corporation plc
Ceregene, Inc.
Domain Therapeutics
Acucela Inc.
Applied Genetic Technologies Corporation
LABORATOIRES THEA
Senju Pharmaceutical Co., Ltd.
Gene Signal International SA.
Promedior, Inc.
Inotek Pharmaceuticals Corporation
Othera Pharmaceuticals, Inc.
CeNeRx BioPharma, Inc.
NOXXON Pharma AG
Aerie Pharmaceuticals, Inc.
SIFI Pharma
Zeltia, S.A.
Mimetogen Pharmaceuticals Inc.
Icon Bioscience, Inc.
Glaucoma - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Saflutan - Drug Profile
Product Description
Mechanism of Action
R&D Progress
iSONEP - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LX7101 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DT0738 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CF101 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CERE-140 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
INO-8875 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ST-802 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PRM-151 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
K-115 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DuoTrav - Drug Profile
Product Description
Mechanism of Action
R&D Progress
QPI-1007 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Myogane - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SNJ-2022 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AR-102 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AR-13165 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AR-12286 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SF103 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SF108 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
OT-440 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SF 109 - Drug Profile
SF 116 - Drug Profile
Bosentan - Drug Profile
DE-090 - Drug Profile
HPP851 - Drug Profile
SMT D003 - Drug Profile
GS-101 - Drug Profile
Cogane - Drug Profile
RKI983 - Drug Profile
AZD4017 - Drug Profile
CXB040 - Drug Profile
CXB070 - Drug Profile
Avastin - Drug Profile
T2345 - Drug Profile
CXB029 - Drug Profile
OPA-6566 - Drug Profile
MIM-D3 - Drug Profile
Avastin - Drug Profile
Avastin - Drug Profile
ISV-215 - Drug Profile
NOX-S91 - Drug Profile
Lucentis - Drug Profile
CXB006 - Drug Profile
DE-112 - Drug Profile
ACN-1052 - Drug Profile
AL-54478 - Drug Profile
DE-111 - Drug Profile
Glaucoma Therapeutics – Drug Profile Updates
Glaucoma Therapeutics - Discontinued Products
Glaucoma - Featured News
Sep 13, 2011: Acucela And Otsuka Pharmaceutical Announce Initiation Of Phase I/II Clinical Trial For OPA-6566 In Patients With Open-Angle Glaucoma Or Ocular Hypertension
Sep 08, 2011: Novagali Pharma Reports Positive Results In Phase II Study For Catioprost Versus Travatan Z In Patients With Glaucoma And Ocular Surface Disease
Jul 21, 2011: Inotek To Expand Phase II Clinical Trial In Glaucoma Based On Promising Preliminary Results
Jul 04, 2011: Sylentis Presents Phase I Trial Results Of SYL040012 In Glaucoma And Ocular Hypertension At World Glaucoma Congress 2011
May 09, 2011: Kowa Presents Phase II Clinical study Results Of K-115 At ARVO 2011
May 01, 2011: Merck’s Investigational Prostaglandin Analogue Ophthalmic Medication Tafluprost Meets Primary Endpoint In Phase III Study
Apr 14, 2011: Novagali Pharma Completes Patients Recruitment For Its US Phase II Clinical Trial of Catioprost
Mar 09, 2011: Merck Announces FDA Acceptance Of New Drug Application For Investigational Ophthalmic Medication SAFLUTAN
Sep 09, 2010: iSONEP Phase I Results Highlighted at Three Major Scientific Meetings
Sep 07, 2010: Promedior Initiates Phase IIa Clinical Study Of PRM-151 In Prevention Of Post-Surgical Scarring In Glaucoma Patients
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Glaucoma, H2 2011
Products under Development for Glaucoma – Comparative Analysis, H2 2011
Number of Products under Development by Companies, H2 2011
Number of Products under Development by Companies, H2 2011
Number of Products under Investigation by Universities/Institutes, H2 2011
Comparative Analysis by Late Stage Development, H2 2011
Comparative Analysis by Mid Clinical Stage Development, H2 2011
Comparative Analysis by Early Clinical Stage Development, H2 2011
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2011
Products under Development by Companies, H2 2011
Products under Development by Companies, H2 2011
Products under Development by Companies, H2 2011
Products under Development by Companies, H2 2011
Products under Development by Companies, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Alcon, Inc., H2 2011
Bausch & Lomb Incorporated, H2 2011
Allergan, Inc., H2 2011
QLT Inc., H2 2011
AstraZeneca PLC, H2 2011
Santen Incorporated, H2 2011
Quark Pharmaceuticals, Inc., H2 2011
Merck & Co., Inc., H2 2011
Santen Pharmaceutical Co., Ltd., H2 2011
Novagali Pharma SA, H2 2011
Alseres Pharmaceuticals, Inc., H2 2011
Kowa Company, Ltd., H2 2011
Pfizer Inc., H2 2011
Sun Pharmaceutical Industries Limited, H2 2011
ISTA Pharmaceuticals, Inc., H2 2011
OphthalmoPharma Ltd., H2 2011
InSite Vision Incorporated, H2 2011
Proneuron Biotechnologies, Inc., H2 2011
Can-Fite BioPharma Ltd., H2 2011
Lpath, Inc., H2 2011
ACADIA Pharmaceuticals Inc., H2 2011
Lexicon Pharmaceuticals, Inc., H2 2011
Phytopharm Plc, H2 2011
Asterand plc., H2 2011
Resverlogix Corp., H2 2011
Sirion Therapeutics, Inc., H2 2011
Summit Corporation plc, H2 2011
Ceregene, Inc., H2 2011
Domain Therapeutics, H2 2011
Acucela Inc., H2 2011
Applied Genetic Technologies Corporation, H2 2011
LABORATOIRES THEA, H2 2011
Senju Pharmaceutical Co., Ltd., H2 2011
Gene Signal International SA., H2 2011
Promedior, Inc., H2 2011
Inotek Pharmaceuticals Corporation, H2 2011
Othera Pharmaceuticals, Inc., H2 2011
CeNeRx BioPharma, Inc., H2 2011
NOXXON Pharma AG, H2 2011
Aerie Pharmaceuticals, Inc., H2 2011
SIFI Pharma, H2 2011
Zeltia, S.A., H2 2011
Mimetogen Pharmaceuticals Inc., H2 2011
Icon Bioscience, Inc., H2 2011
Assessment by Monotherapy Products, H2 2011
Assessment by Combination Products
Assessment by Stage and Route of Administration, H2 2011
Assessment by Molecule Type, H2 2011
Glaucoma Therapeutics – Drug Profile Updates
Discontinued Products

List of Figures
Number of Products under Development for Glaucoma, H2 2011
Products under Development for Glaucoma – Comparative Analysis, H2 2011
Products under Development by Companies, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Late Stage Products, H2 2011
Mid Clinical Stage Products, H2 2011
Early Clinical Stage Products, H2 2011
Discovery and Pre-Clinical Stage Products, H2 2011
Assessment by Monotherapy Products, H2 2011
Assessment by Combination Products, H2 2011
Assessment by Route of Administration, H2 2011
Assessment by Stage and Route of Administration, H2 2011
Assessment by Molecule Type, H2 2011
Assessment by Stage and Molecule Type, H2 2011

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos